Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids

• Status: Completed
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to measure the safety (side effects) of an Omega 3 Fatty acid called docosahexanoic acid (DHA) and measure the dyskinesia (involuntary movements) in Parkinson 's disease (PD).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VA Office of Research and Development
• Collaborator: Oregon Health and Science University

Criteria

Inclusion Criteria:

• Diagnosed with Parkinsons disease

• No levodopa (Sinemet) treatment or prior exposure to levodopa

Exclusion Criteria:

• Prior exposure to levodopa

• Unable to stand for 1 minute without aid

• Sensory deficits on feet

• Significant cognitive impairment

• Current use of dopamine receptor blocking medications (depakote, lithium, amiodarone, tetrabenazine, metoclopramide, dronabinol)

• Current fish oil or lutein supplementation

• Allergy to soy